Bluewater Bio Explores Strategic Sale with Advisory Support

Bluewater Bio, a leader in water treatment technology, is exploring a potential sale with advisory support from Rothschild & Co and BDA. With founder Salica at the helm, the company has garnered significant attention from potential investors, thanks to its robust growth and innovative technologies like HYBACS and FilterClear. 

Over the past three years, Bluewater Bio has achieved a remarkable 38% annual compound growth rate. Particularly noteworthy is its FilterClear technology, which has seen 83% growth in the same timeframe. As an exporter primarily beyond the US market, Bluewater Bio remains resilient against fluctuating tariffs, providing a steady footing amidst economic uncertainties. The UK and Middle East markets are key focus areas, with recent agreements poised to open new avenues for expansion. The company’s well-established technologies, particularly in phosphorus removal and desalination pretreatment, align with the UK’s ongoing environmental enhancement initiatives expected to continue through 2035.